Qelbree (viloxazine) treats ADHD by increasing levels of norepinephrine and serotonin in the brain’s prefrontal cortex, the region responsible for attention, impulse control, and planning. Unlike stimulant medications, it is not a controlled substance and carries no evidence of drug dependence. It was FDA-approved for children ages 6 to 17 in 2021 and for adults in 2022, but the active ingredient has a longer track record: viloxazine was first used in Europe in 1974 as an antidepressant and was prescribed there for roughly 30 years before being reformulated as an extended-release capsule for ADHD in the United States.
How Qelbree Affects Brain Chemistry
Qelbree’s core action is blocking the norepinephrine transporter (NET), a protein that pulls norepinephrine back into nerve cells after it’s been released. By slowing this recycling process, more norepinephrine stays available in the spaces between neurons. Norepinephrine is critical for sustaining attention, staying alert, and managing impulses, which are the exact functions that falter in ADHD.
What makes Qelbree more complex than a simple norepinephrine booster is its significant activity on the serotonin system. Researchers now classify it as a “serotonin norepinephrine modulating agent” because its serotonin effects appear to be just as important as its norepinephrine effects. In animal studies, Qelbree raised serotonin levels in the prefrontal cortex and also increased dopamine levels there as a downstream consequence of blocking the norepinephrine transporter.
At the receptor level, Qelbree partially activates one type of serotonin receptor (5-HT2C) and blocks two others (5-HT2B and 5-HT7). At the doses used for ADHD, the drug occupies more than 80% of those first two receptor types and about 65% of the third. Activating the 5-HT2C receptor is thought to help regulate impulsivity and appetite, while blocking the other two may contribute to improvements in mood and cognition. This blend of effects distinguishes Qelbree from both stimulants and older non-stimulant options.
Why It’s Not a Stimulant
Stimulant medications for ADHD, like amphetamine and methylphenidate, work primarily by flooding the brain with dopamine. That dopamine surge is what makes them effective but also what gives them a high potential for abuse and physical dependence. They are classified as Schedule II controlled substances.
Qelbree takes a different route. It has almost no ability to bind to the dopamine transporter (its binding affinity for that transporter is essentially negligible), so it doesn’t produce the rapid dopamine spike associated with stimulants. It does modestly raise dopamine in the prefrontal cortex, but this happens indirectly through norepinephrine transporter blockade rather than through direct dopamine transporter activity. The result is that Qelbree produces what researchers describe as a “stimulant-like effect” on attention and focus without the reinforcing high that drives misuse. It is not a controlled substance.
How Long It Takes to Work
Qelbree is not a medication you feel working on the first day the way a stimulant might be. In clinical trials, meaningful symptom improvement showed up around week four. In one eight-week study, patients saw their ADHD symptom scores drop by about 13.5 points at the four-week mark and by 18.2 points at eight weeks, a pattern of gradual, continuing improvement rather than an immediate on-off switch. This timeline is typical for non-stimulant ADHD medications and is something to keep in mind if you’re starting treatment: giving the drug a full month or more before judging its effectiveness is reasonable.
How Effective It Is in Trials
In a randomized, placebo-controlled trial in adults, Qelbree reduced ADHD symptom scores by 15.5 points from baseline compared to 11.7 points for placebo, a statistically significant difference. That gap of nearly four points may sound modest in raw numbers, but on standardized rating scales it represents a clinically noticeable improvement in the ability to focus, stay organized, and control impulsive behavior. The drug has also been studied as an add-on to stimulants for patients who get partial relief from a stimulant alone, with results showing further symptom reduction when the two are combined.
Dosing and How It’s Taken
Qelbree is taken once daily as an extended-release capsule, with or without food. Starting doses and maximum doses differ by age group:
- Children ages 6 to 11: Start at 100 mg daily, increasing by 100 mg each week up to a maximum of 400 mg daily.
- Adolescents ages 12 to 17: Start at 200 mg daily, with the option to increase to 400 mg after one week.
- Adults: Start at 200 mg daily, increasing by 200 mg weekly up to a maximum of 600 mg daily.
Dose increases are made based on how well symptoms respond and how well the medication is tolerated. The capsules can be opened and sprinkled on applesauce for children who can’t swallow pills.
The Caffeine Interaction
One practical detail that often surprises people: Qelbree strongly inhibits a liver enzyme called CYP1A2, which is the main enzyme your body uses to break down caffeine. In a pharmacology study, taking Qelbree alongside caffeine didn’t change peak caffeine levels, but it increased total caffeine exposure by roughly four to five times and significantly extended how long caffeine stayed in the body. If you drink coffee, tea, or energy drinks while on Qelbree, you may feel the effects of caffeine far more intensely and for much longer than you’re used to. This can contribute to insomnia, jitteriness, or increased heart rate. Reducing caffeine intake is a straightforward way to avoid these amplified effects.
This same enzyme interaction also affects the breakdown of certain other medications. Your prescriber should review your full medication list before starting Qelbree.
The Suicidal Thoughts Warning
Qelbree carries a boxed warning, the FDA’s most serious label warning, about an increased risk of suicidal thoughts and behavior in children, adolescents, and young adults. This warning applies to all medications that affect norepinephrine and serotonin signaling and is not unique to Qelbree. The risk is highest during the first few months of treatment or when the dose changes. Monitoring for new or worsening mood symptoms, especially in the early weeks, is standard practice when starting this medication.